Private Equity News Europe – NLC, a Dutch venture builder and investor in healthtech startups, has announced a new €20 million fund to support the development of early-stage companies.
The fund, called the NLC Impact Health Fund, will invest in startups that are developing innovative solutions to some of the world’s most pressing health challenges. NLC is particularly interested in companies that are using technology to improve healthcare delivery, diagnostics, and treatments.
European Private Equity News
The fund will be managed by NLC’s team of experienced healthcare investors. NLC has a strong track record of investing in and growing healthtech companies. The firm’s portfolio includes companies such as Doctena, a digital healthcare platform, and Validic, a data analytics company.
In a statement, NLC said:
“We are excited to announce the launch of the NLC Impact Health Fund. We believe that this fund will play a key role in supporting the development of innovative healthtech companies that are making a real difference in the world.”
The NLC Impact Health Fund is expected to invest in 10-15 companies over the next few years. The fund will focus on companies that are based in Europe, but it is open to considering companies from other regions.
The launch of the NLC Impact Health Fund is a sign of the growing interest in healthtech investment. The healthtech market is expected to reach $513 billion by 2025, and there is a growing demand for investment in innovative healthtech companies.
Private Equity News Europe
